AstraZeneca shares fell 9% in London trading after a late‑stage trial of its heart drug Wainua failed to hit its primary endpoint. The partnership with Ionis had raised expectations for a therapy targeting transthyretin‑mediated amyloid cardiomyopathy.

The Phase 3 study showed no statistically significant benefit in reducing cardiovascular deaths among patients, a group estimated at 300,000-500,000 worldwide. This loss marks a second setback for the company in a short span, following a May regulator delay on a separate oncology treatment.

Investor reaction highlights growing concern over the company’s research pipeline. While AstraZeneca celebrated 16 positive late‑stage results last year, the Wainua failure may prompt analysts to adjust earnings forecasts and reassess the drugASN portfolio.

Market implications include a potential decline in valuation metrics and a shift in investor focus toward the company’s other therapeutic avenues. The setback may accelerate the urgency to develop alternative treatments and could influence future capital allocation decisions.